<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| CARC-6/PanNET-7 Internal Request: Institutional review comment to review data for the inclusion of lanreotide. | Based on the data in the noted references and discussion, the panel consensus was to add lanreotide. This regimen was added with a category 2A recommendation for the following indications:  
- Neuroendocrine Tumors of the GI Tract, Lung and Thymus (Carcinoid Tumors)  
  o Management of unresectable locoregional disease and/or distant metastases for asymptomatic/low tumor burden, clinically significant tumor burden, carcinoid syndrome, and clinically significant progressive disease (CARC-6)  
  o Treatment of Zollinger-Ellison syndrome in patients with gastric neuroendocrine tumors (CARC-4)  
- Neuroendocrine Tumors of the Pancreas  
  o Consider for symptom control in patients with locoregional gastrinomas. (PanNET-2)  
  o For symptom control in patients with locoregional glucagonomas or VIPomas. (PanNET-4; PanNET-5)  
  o For the management of locoregional unresectable disease and/or distant metastases (PanNET-7):  
    ▪ Consider for asymptomatic, low tumor burden, and stable disease.  